231 related articles for article (PubMed ID: 33605797)
1. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
3. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L
Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status.
Attia S; Abd El Hafez A; Abdel-Aziz A; Elmetwaly S; Mokhtar N
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1433-1444. PubMed ID: 35485706
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
Liu Y; Wang JF; Li XW; Bu P; Bai W; Li LM
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):597-602. PubMed ID: 30107664
[No Abstract] [Full Text] [Related]
8. PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study.
Beer A; Taghizadeh H; Schiefer AI; Puhr HC; Karner AK; Jomrich G; Schoppmann SF; Kain R; Preusser M; Ilhan-Mutlu A
Pathol Oncol Res; 2020 Oct; 26(4):2225-2235. PubMed ID: 32372174
[TBL] [Abstract][Full Text] [Related]
9. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance.
Lian J; Zhang G; Zhang Y; Liu H; Zhang J; Nan P; Tian W
Dig Liver Dis; 2022 Oct; 54(10):1419-1427. PubMed ID: 35123909
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and tumor infiltrating PD-1+Â lymphocytes associated with outcome in HER2+Â breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.
Qing Y; Li Q; Ren T; Xia W; Peng Y; Liu GL; Luo H; Yang YX; Dai XY; Zhou SF; Wang D
Drug Des Devel Ther; 2015; 9():901-9. PubMed ID: 25733810
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
16. Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer.
He PX; Ma ZL; Han H; Zhang XY; Niu SH; Du LN; Zheng YC; Liu HM
Life Sci; 2020 Feb; 242():117247. PubMed ID: 31899223
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma.
Sughayer MA; Dabbagh TZ; Battah AH
Appl Immunohistochem Mol Morphol; 2020; 28(10):748-754. PubMed ID: 32205740
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
Zhang M; Dong Y; Liu H; Wang Y; Zhao S; Xuan Q; Wang Y; Zhang Q
Sci Rep; 2016 Nov; 6():37933. PubMed ID: 27892511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
